Juva Life (OTC: JUVAF) is a life sciences research company with an immense background in cannabis, allowing the company to cultivate and to derive small molecule compounds that target inflammation in the human body. Currently Juva Life is working with Juva-019 and Juva-041, which are non-cannabinoid molecules found to be naturally occurring in the cannabis plant. Juva Life’s assets include one micro business, one cannabis cultivation facility and two cannabis delivery companies in California. The company was founded by Doug Chloupek in 2018, with the ultimate goal of bringing together a hand-picked team of cannabis industry veterans and leading, highly-respected medical researchers to create rigorously-tested, consistent, quality products built on research and a retail system that fosters informed customers through education and science.
Doug has an immense background in both medical and adult-use cannabis, and was the visionary, co-founder, and COO of BAS Research. BAS Research (BAS) was California’s first licensed medical cannabis manufacturing and research group, dedicated to developing breakthrough pharmaceutical-grade cannabis products. He is a strong believer that standardized dosing and research is the first step to confirming the effectiveness of medical cannabis. The pharmaceutical industry follows an existing set of processes, and takes many different pathways to achieve an ultimate goal. Juva Life is taking a chemical approach to research versus a biological one, and is using modern tools to identify potential answers. In short, cannabis is known to anecdotally reduce pain and inflammation – Juva Life’s goal is to identify how and why this works, and isolate the specific molecules responsible for positive pain management effects in humans.
Full name: Doug Chloupek
Title: Founder, CEO, and Chairman of the Board
Company: Juva Life
Years at current company: 4
Education profile: I took an atypical route – I graduated high school 2 years early, and college wasn’t for me. I worked hard as a young person, homeschooled myself and have been working a 40/hr week job since age 15.
Most successful professional accomplishment before cannabis:
Over the past 12 years, I have led and created seven successful cannabis businesses, including the operation of cannabis retail businesses for 9 of those years, cultivation businesses for 8 of those years, and manufacturing businesses for 6 of those years. Prior to joining the cannabis industry, I acquired an additional 12 years of experience in marketing, brand creation, and advertising. I had been in media sales for about a decade, launched an online advertising/marketing firm for attorneys back in 2005, and had an entertainment company booking entertainers for local venues. Unlocking the health benefits hidden in cannabis was the motivating and all-consuming factor to create Juva and has brought us to where we are today.
The Company’s mission is to leverage its unique knowledge of the chemistry and anti-inflammatory properties contained within cannabis to develop safe and effective therapeutics. We believe there are unappreciated small molecules identified by Juva and found in the cannabis plant that hold the keys to regulating inflammation in the human body. Our team of scientists are doing the much-needed research to validate our findings using established pharmaceutical assays to prove their efficacy.
Company’s most successful achievement:
The discoveries of proprietary non-cannabinoid molecules, JUVA-019 and JUVA-041.
Juva-019 is a molecule found and derived from cannabis. It is a non-cannabinoid molecule, which is a naturally occurring molecule that is different from THC and CBD, with no psychoactive effects. Juva Life’s research team discovered Juva-019 by screening the whole library of compounds in cannabis using standard pharmaceutical assays, looking for compounds that stood out for their anti-inflammatory properties.
Juva-041 is unique in that it actually inhibits multiple cytokines, which are responsible for inflammation in the human body. Juva Life’s researchers expect Juva-041 to have a potentially broader application than Juva-019, and have identified a process for straightforward, inexpensive synthesis of this molecule, without having to cultivate cannabis.
Has the company raised any capital (yes or no)? If so, how much?:
Yes, $36 million to date
Any plans on raising capital in the future?
Most important company 5 year goal:
Juva Life’s goal is to unlock the secret of cannabis’ relationship with inflammation and pain management. Our team’s deep research background brings together top experts across multiple disciplines to apply a level of science and rigor not historically seen in the cannabis industry. At the core of its research, Juva Life is embarking to discover why and how cannabis works, and who it works for. With the recent discoveries of JUVA-019 and JUVA-041, we believe we are well on track to accomplish this goal.
psychoactive otc synthesis research